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Abstract
Introduction: Atrial fibrillation (AF) and diabetes mellitus (DM) constitute a heavy 
burden on healthcare expenditure due to their negative impact on clinical outcomes 
in the Middle East. The Atrial fibrillation Better Care (ABC) pathway provides a sim-
ple strategy of integrated approach of AF management: A—Avoid stroke; B—Better 
symptom control; C—Cardiovascular comorbidity risk management.
Aims: Evaluation of the AF treatment compliance to ABC pathway in DM patients in 
the Middle East. Assessment of the impact of ABC pathway adherence on all-cause 
mortality and the composite outcome of stroke/systemic embolism, all-cause death 
and cardiovascular hospitalisations.
Methods: From 2043 patients in the Gulf SAFE registry, 603 patients (mean age 
63; 48% male) with DM were included in an analysis of ABC pathway compliance: 
A—appropriate use of anticoagulation according to CHA2DS2-VASc score; B—
AF symptoms management according to the European Heart Rhythm Association 
(EHRA) scale; C—Optimised cardiovascular comorbidities management.
Results: 86 (14.3%) patients were treated in compliance with the ABC pathway. 
During 1-year follow-up, 207 composite outcome events and 87 deaths occurred. 
Mortality was significantly lower in the ABC group vs non-ABC (5.8% vs 15.9%, 
P = .0014, respectively). On multivariate analysis, ABC compliance was associated 
with a lower risk of all-cause death and the composite outcome after 6 months (OR 
0.18; 95% CI: 0.42-0.75 and OR 0.54; 95% Cl: 0.30-1.00, respectively) and at 1 year 
(OR 0.30; 95% Cl: 0.11-0.76 and OR 0.57; 95% Cl: 0.33-0.97, respectively) vs the 
non-ABC group.
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1 |  INTRODUCTION
Atrial Fibrillation (AF) is a leading cause of cardiovascular 
death as well as disability and impaired quality of life by 
exacerbating other underlying comorbidities such as heart 
failure, stroke or dementia.1-5 Furthermore, AF is a growing 
epidemic is associated with high costs of treatment and hos-
pitalisations, thus having significant implications for health-
care costs.4,6,7
Similarly, for diabetes mellitus (DM), the latest estimates 
show a steadily increasing trend in the numbers of such pa-
tients. By the end of 2045, the number of DM patients is ex-
pected to reach 700 million, which represents an increase by 
around 40%.8 Indeed, the Middle East is one of the world's 
regions where the growth of people with diabetes is predicted 
to be the largest over the next few years, and the prevalence 
is increasing8 This is even more important given that DM 
is a well-established risk factor for many cardiovascular dis-
eases, including AF.9,10 Many studies report the common co-
existence of AF and DM, and their associated cardiovascular 
risks.7,11-15 Hence, patients with DM are not only more likely 
to develop AF during their life, but they also have a signifi-
cantly higher overall risk of cardiovascular complications.16,17
Given the multifactorial background of AF, a more in-
tegrated and holistic approach to AF management with op-
timised drug therapies may improve clinical outcomes.18-20 
The Atrial fibrillation Better Care (ABC) pathway for inte-
grated care of AF patients is a simple strategy showing step-
by-step how to approach AF management in a comprehensive 
and sensible way.5 The ABC pathway refers to the following 
steps: Avoid stroke with Anticoagulation (A); Better symp-
tom management with patient-centred symptom-directed 
decisions on rate or rhythm control (B); Cardiovascular and 
comorbidity risk optimisation (C). The ‘A’ criterion refers 
to optimisation of stroke prevention, which involves initial 
identification of low-risk patients, who are not recommended 
any antithrombotic therapy. Following this, patients with ≥1 
stroke risk factors are considered for OAC and would require 
assessment of bleeding risk and decision-making on OAC 
type.5 The ‘B’ criterion refers to symptom assessment of the 
patient with AF and deciding the initial treatment strategy to 
be established with rate control drugs or rhythm control with 
antiarrhythmic drugs or electrophysiological procedures. The 
‘C’ criterion refers to effective management of comorbidities 
as well as patient involvement with lifestyle changes, dietary 
habits or physical activity.5 The above-mentioned holistic 
care approach facilitates risk reduction through effective 
treatment of accompanying diseases, whereby DM is one of 
the most prominent examples.5
In this study, we evaluated whether the management of 
AF patients with concomitant DM in the Middle East region 
was generally compliant with the ABC regimen, based on 
a ‘real-world’ dataset enrolled in the Gulf Survey of Atrial 
Fibrillation Events (Gulf SAFE registry). Second, the impact 
of ABC pathway compliant management on adverse clinical 
outcomes. The adherence to the ABC pathway and its impact 
on clinical outcomes has never been previously evaluated in 
this Middle Eastern population.
2 |  METHODS
The Gulf SAFE dataset is a multi-centre, observational, pro-
spective cohort study recording subsequent AF patients from 
6 countries in the Gulf region of the Middle East. Details on 
the methods have been described in the previously published 
papers.21 Briefly, the register consists of AF patients admit-
ted to ER from 23 participating hospitals between October 
15, 2009, and June 30, 2010, regardless of the primary rea-
son for admission. The qualifying criterion was age over 
18 years and the duration of AF >30 seconds on a 12-lead 
resting electrocardiogram. Consequently, the Gulf SAFE 
registry had 2043 participants. All patients gave informed 
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Conclusions: Compliance with the ABC pathway care was independently associated 
with the reduced risk of all-cause death and the composite outcome in DM patients 
with AF, highlighting the importance of an integrated approach to AF management.
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Novelty statement
• Most AF patients with diabetes are not optimally 
treated despite having a high risk of stroke.
• Integrated optimal treatment, according to the 
ABC pathway regimen, reduces the risk of all-
cause mortality and composite outcome.
• The substantial mortality and composite outcome 
risk reduction in ABC compliant group is inde-
pendent either of the duration of follow up and 
other adjusted risk factors.
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consent for their participation after being informed about the 
details of the study. The study received approval from the 
ethics committees of each institution/country and conforms 
to recognised standards. For the purposes of this study, we 
included only patients with AF and DM, and this cohort of 
603 patients was analysed.
We analysed compliance in line with the ABC path-
way components, which were defined on the basis of ESC 
Guidelines22 as follows:
• ‘A’ -avoid stroke: All AF patients with DM have a high 
risk of stroke (CHA2DS2-VASc score of ≥1 in men or ≥2 
in women), and therefore, we assessed whether subjects 
were treated with OAC (‘A compliant’). Those who did 
not receive OACs were considered as ‘A noncompliant’. 
The vast majority of patients receiving OAC in the current 
study were administered with vitamin K antagonists (VKA 
eg warfarin).
• ‘B- better symptoms control’: We evaluated the occur-
rence of symptoms and classified them according to the 
European Heart Rhythm Association (EHRA) symptom 
scale. We assumed that patients with EHRA I or II had 
well-controlled AF symptoms (‘B compliant’) in compar-
ison to those with EHRA III or IV, who were more symp-
tomatic and treated insufficiently (‘B noncompliant’).
• ‘C- Cardiovascular and other comorbidities’: To reduce 
cardiovascular risk, we evaluated appropriate treatment(s) 
of the following comorbidities based on available data: 
hypertension (HT), coronary artery disease (CAD), pe-
ripheral artery disease (PAD), stroke/TIA. HT assessment 
was based on an average of blood pressure values at hos-
pital admission that should be <140/90 mm Hg in order 
to be considered as well controlled. For other comorbid-
ities, optimal pharmacologic management was evaluated 
in accordance with the current European guidelines and 
recommendations (Figure 1). ‘C compliant’ means that all 
comorbidities were either well-controlled or treated with 
appropriate prevention drugs or both. Finally, patients who 
met all criteria were defined as the ‘ABC group’, and those 
who did not meet all criteria were the ‘Non-ABC’ group.
2.1 | Outcomes
In our analysis, we assessed all-cause mortality and a com-
posite outcome, which consists of the following events that 
occurred during follow-up: stroke or systemic embolism, all-
cause death and cardiovascular hospitalisation. The primary 
analysis was a comparison of the above-mentioned outcomes 
between patients with integrated care management in accord-
ance with the ABC pathway (ABC group), compared to those 
without ABC pathway compliance (non-ABC group).
2.2 | Statistical analysis
Continuous variables were reported as mean  ±  standard de-
viation and evaluated by Student's t test or Mann-Whitney, as 
necessary. Categorical variables were expressed as percentages 
and counts and compared using Pearson's chi-square test or 
Fisher's exact test, as appropriate. All the patients included a 
further assessment to have AF and DM. The major analyses 
were based on the comparison of the clinical outcomes between 
two study groups: ABC group vs the non-ABC group, whereby 
the former reflects compliance with the ABC pathway in AF 
management while the latter does not. The secondary analysis 
evaluated the impact of the total number of ABC steps fulfilled, 
the partial compliance with ABC regimen (0 or 1 ABC fulfilled 
criteria vs 2 of 3 fulfilled ABC criteria) and particular criteria 
met (A, B or C) on the major clinical outcomes, that is, all-
cause mortality and composite outcome.
F I G U R E  1  Methodology scheme 
of the evaluation of AF management 
compliance with ABC pathway components. 
For details, see text
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Odds ratios (ORs) were analysed using multivariable lo-
gistic regression model and were used according to the out-
comes considered. All multivariable regression models were 
adjusted for AF type, renal dysfunction, dyslipidemia, use 
of aspirin and major bleeding, which are well-known risk 
factors for all-cause mortality and the composite outcome 
components.
All tests were 2-sided and P value <.05 was considered 
as statistically significant. Analyses were performed with the 
SPSS version 24 software package (SPSS Inc).
3 |  RESULTS
From 2043 patients with AF enrolled in the Gulf SAFE reg-
istry, there were 603 (30%) patients with concomitant DM, 
who were included in the analysis. Overall, 86 (14.3%) pa-
tients were treated optimally according to ABC pathway. 
Baseline characteristics of the study cohort are presented 
in Table 1. Patients from the ABC group and the non-ABC 
group did not significantly differ in terms of gender, age 
and BMI.
Compared to the non-ABC group, patients in ABC 
group had lower mean systolic and diastolic blood pres-
sure (both P < .001), suffered more frequent due to chronic 
kidney disease (P =  .021). Patients from ABC compliant 
group were also administered a larger number of medica-
tions (Table. 1).
3.1 | ‘A’ compliance and 
anticoagulation management
All 603 patients included in the analysis were at high stroke 
risk (CHA2DS2-VASc score ≥2 for women or ≥1 for men) 
therefore required anticoagulant therapy. There were 349 
(57.9%) patients in the study cohort treated in line with ‘A’ 
(Table 2). Of these, 151 (25.1%) were treated with an OAC 
monotherapy, 142 (23.5%) received dual antithrombotic 
therapy and 25 (4.2%) received triple antithrombotic therapy, 
while 34 (5.6%) had no anticoagulant/antiplatelet therapy at 
all. A detailed description of OAC management is presented 
in Table S1.
3.2 | ‘B’ compliance and symptoms control
In the cohort, there were 441 (73.1%) well-managed patients 
with either EHRA I-II scores, who were categorised as B 
compliant. Of these, 182 (30.1%) patients were asymptomatic 
(EHRA I) and 259 (53.0%) had mild symptoms (EHRA ≤ 2), 
mostly palpitations (56.1%).
3.3 | ‘C’ compliance and comorbidities risk 
optimisation
Of the whole cohort, 183 (30.3%) were optimally treated for 
comorbidities. HT was the most prevalent associated disease 
(78.1%). Treatment regimens and the prevalence of concomi-
tant diseases are summarised in Table S2.
3.4 | ABC compliance and clinical outcomes
After adjusting for clinical variables, we analysed the risk 
of all-cause mortality and the composite outcome after 
6 months and 1 year of follow-up (Table 3). In this time 
period, 207 composite outcome events occurred, and 87 
individuals died.
The mortality rate was significantly lower in ABC group 
comparing to noncompliant ABC patients (5.8% vs 15.9%, 
P = .014, respectively). A nonsignificant trend was observed 
in the comparison of the composite outcome rates between 
ABC and non-ABC groups (25.6% vs 36.8%, P  =  .065, 
respectively).
In a multivariable regression analysis, the ABC pathway 
was independently associated with a significantly reduced 
risk of all-cause death and the composite outcome after 
6 months (OR 0.18; 95% CI, 0.42-0.75 and OR 0.54; 95% 
Cl, 0.30-1.00, respectively) and at 1 year (OR 0.30; 95% Cl, 
0.11-0.76 and OR 0.57; 95% Cl, 0.33-0.97, respectively) in 
comparison to the non-ABC compliant group (Table 3 and 
Figure 2).
Considering the components of partially fulfilled ABC 
criteria, there was no statistically significant impact on all-
cause mortality and composite outcome after 1 year of fol-
low-up, when only 2 of 3 criteria were met (AB or BC or 
AC) except for BC compliance, which was associated with 
lower risk of composite outcome (OR 0.58, 95% Cl, 0.37-
0.91) after 1 year (Table 4).
4 |  DISCUSSION
This is the first study analysing the compliance of AF man-
agement in accordance with the ABC pathway among pa-
tients with AF and concomitant DM, based on a real-world 
observational trial in the Middle East which has a high preva-
lence of DM. Our study shows that the vast majority of these 
patients were not managed optimally despite having a high 
risk of stroke. Second, optimal integrated treatment fulfill-
ing all criteria in the ABC pathway regimen significantly 
reduced the risk of all-cause mortality and the composite out-
come in comparison to the non-ABC compliant group. Third, 
the lower risk of mortality and composite outcome in ABC 
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T A B L E  1  Baseline characteristics of the study cohort
Characteristics
All patients 
(n = 603) ABC group (n = 86) Non-ABC group (n = 517)
P 
value
Demographics
Male gender, n (%) 288 (47.8%) 42 (48.8%) 246 (47.6%) .829
Age, mean ± SD 63.42 ± 11.75 64.8 ± 10.79 63.20 ± 11.92 .253
Weight (kg), mean ± SD 80.69 ± 17.35 83.35 ± 17.96
n = 82
80.25 ± 17.22
n = 495
.135
Height (cm), mean ± SD 163.92 ± 8.94 163.81 ± 9.2
n = 80
163.93 ± 8.90
n = 485
.910
BMI, mean ± SD 30.11 ± 6.30 31.36 ± 7.33
n = 80
29.91 ± 6.10
n = 483
.056
Systolic BP (mm Hg) mean ± SD 134.68 ± 26.20 121.44 ± 13.49 136.89 ± 27.14 <.001
Diastolic BP (mm Hg) mean ± SD 79.91 ± 15.79 72.77 ± 9.85 81.10 ± 16.27 <.001
Comorbidities, n (%)
Coronary artery disease, n (%) 284 (47.1%) n = 598 48 (55.8%) 236 (46.1%)
n = 512
.095
Hypertension, n (%) 490 (81.3%) 69 (80.2%) 421 (81.4%) .792
Dyslipidemia, n (%) 358 (59.4%) n = 597 63 (73.3%) 295 (57.7%)
n = 511
.007
Heart failure, n (%) 202 (33.5%) 28 (32.6%) 174 (33.7%) .842
Stroke or TIA, n (%) 90 (14.9%) 8 (9.3%) 82 (15.9%) .114
Peripheral artery disease, n (%) 6 (7.0%) 23 (4.4%) .310
Sleep Apnoea, n (%) 9 (1.7%) 2 (2.4%)
n = 85
.698
Dementia or cognitive defects, n (%) 0 (0%) 28 (5.4%) .072
Chronic kidney disease n (%) 64 (10.6%) 61 (11.8%) 3 (3.5%) .021
Stroke or bleeding risk scores
CHA2DS2-VASc, mean ± SD 3.69 ± 1.58 3.60 ± 1.27 3.70 ± 1.63 .604
HAS-BLED, mean ± SD 1.56 ± 1.07 1.38 ± 0.83 1.59 ± 1.1 .096
Echocardiogram
Left atrium diameter (mm) 43.68 ± 7.94 44.22 ± 7.3
n = 58
43.59 ± 8.03
n = 366
.579
LVEF (%), n = 1490 48.91 ± 14.00 48.93 ± 14.53
n = 60
48.91 ± 13.93
n = 379
.991
Medications, n (%) n = 579, ABC group n = 86, non-ABC group n = 493
ACEI 256 (42.5%) 58 (67.4%) 198 (40.2% <.001
ARB 129 (21.4%) 28 (32.6%) 101 (20.5%) .013
Aspirin 360 (59.7%) 55 (64.0%) 305 (61.9%) .713
Beta-blocker 338 (56.1%) 62 (72.1%) 276 (56.0%) .005
Verapamil or Diltiazem 68 (11.3%) 4 (4.7%) 64 (13.0%) .027
Other calcium channel blocker 79 (13.1%) 6 (7.0%) 73 (14.8%) .051
Clopidogrel 98 (16.3%) 13 (15.1%) 85 (17.2%) .628
Diuretics 301 (49.9%) 51 (59.3%) 250 (50.7%) .141
Digoxin 191 (31.7%) 24 (27.9%) 167 (33.9%) .277
Statin 423 (70.1%) 83 (96.5%) 340 (69.0%) <.001
Other lipid-lowering drug 13 (2.2%) 4 (4.7%) 9 (1.8%) .103
Warfarin 336 (55.7%) 84 (97.7%) 252 (51.1%) <.001
(Continues)
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group was independent of either of the duration of follow up 
and other adjusted covariables.
Our findings indicate that a low percentage of patients 
received comprehensive AF treatment, compliant with ABC 
pathway (14.3%) are consistent with other studies on the sub-
ject.23-25 Stroke prevention and proper AF management are 
even more important among AF patients with concomitant 
DM as it increases the risk of death from unfavourable throm-
botic events.26,27 Moreover, AF patients with DM have a high 
risk of stroke (CHA2DS2-VASc ≥ 1), and the age threshold 
for initiating OAC in an AF patient with DM as his/her only 
stroke risk factor is 50 years.28 Hence, anticoagulation should 
have been implemented to all patients in the DM cohort 
group, while slightly <50% of them were not prescribed OAC 
at all. Despite the high risk of stroke associated with AF, only 
7%-10% die from stroke.29,30 The vast majority of deaths are 
related to cardiovascular complications, especially from heart 
failure. The ABC pathway underlines the need of proper and 
holistic symptom control of concomitant diseases and their 
associated symptoms. This means that not only appropriate 
anticoagulation, but also optimal management and control of 
other symptoms and comorbidities lead to reductions in all-
cause death and the composite outcome.29 indeed, AF can be 
associated with a high mortality despite high overall rates of 
anticoagulation.18
Our study revealed that only holistic AF management in ac-
cordance with all ABC components is related to a reduction in 
either all-cause mortality or occurrence of the composite out-
come. Similarly, Pastori et al31 showed that the risk of adverse 
cardiovascular events raised with the number of uncontrolled 
risk factors. In a clinical trial cohort with adjudicated outcomes, 
Proietti et al reported progressively lower total risk for all-
cause death and composite outcome across the groups with the 
increasing number of fulfilled ABC components.23 The same 
Characteristics
All patients 
(n = 603) ABC group (n = 86) Non-ABC group (n = 517)
P 
value
Other anticoagulant 44 (7.3%) 6 (7.0%) 38 (7.7%) .813
Amiodarone 53 (8.8%) 13 (15.1%) 40 (8.1%) .038
Flecainide 1 (0.2%) 1 (1.2%) 0 (0%) .017
Propafenone 8 (1.3%) 0 (0%) 8 (1.6%) .234
Sotalol 5 (0.8%) 1 (1.2%) 4 (0.8%) .745
Note: High stroke risk: ♀CHAsDSs-VASc ≥ 2, ♂ CHAsDSs-VASc ≥ 1.
Abbreviations: ACEI, angiotensin-converting-enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index, LVEF, left ventricular ejection fraction, 
TIA, transient ischaemic attack.
T A B L E  1  (Continued)
T A B L E  2  ABC pathway compliance
Study group Compliance Noncompliance
A 349 (57.9%) 254 (42.1%)
B 441 (73.1%) 162 (26%)
C 183 (30.3%) 401 (66.5%)
ABC 86 (14.3%) 517 (85.7%)
Abbreviations: A, anticoagulation, B, symptoms management, C, cardiovascular 
and other comorbidities treatment.
T A B L E  3  Multivariable analyses of all-cause mortality and the composite outcome
Risk factors
All-cause mortality Composite outcome
6 mo 1 y 6 mo 1 y
OR (95% CI)
P 
value OR (95% CI)
P 
value OR (95% CI)
P 
value OR (95% CI)
P 
value
AF Type (paroxysmal vs 
persistent/permanent)
1.28 (0.94-1.75) .118 1.45 (1.11-1.90) .007 1.36 (1.10-1.69) .005 1.36 (1.11-1.65) .002
Dyslipidemia 1.49 (0.83-2.68) .187 1.23 (0.75- 2.01) .413 1.25 (0.83-1.87) .286 1.08 (0.75- 1.55) .694
Chronic kidney disease 1.80 (0.87-3.75) .114 1.73 (0.91-3.31) .095 1.58 (0.90-1.87) .114 1.59 (0.93-2.73) .090
Major bleeding 2.64 (0.89-7.84) .081 2.71 (1.02-7.22) .046 2.75 (1.10-6.84) .030 2.62 (1.04-6.61) .042
ASA used 0.67 
(0.38- 1.18)
.163 0.84 (0.52-1.35) .469 1.15 
(0.78- 1.71)
.483 1.20 (0.84-1.72) .319
ABC compliance 0.18 (0.04-0.75) .019 0.29 (0.11-0.76) .012 0.54 (0.30-1.00) .049 0.57 (0.33-0.97) .038
Abbreviations: A, anticoagulation;AF, atrial fibrillation; ASA, acetylsalicylic acid; B, symptoms management; C, cardiovascular and other comorbidities treatment; CI, 
confidence interval, OR, odds ratio.
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trend was presented in a nationwide cohort study based on an 
Asian population.25 The above evidence indicates the value 
of compliance with the ABC pathway for reducing the risk of 
death and composite adverse outcomes and highlights the im-
portance of integrated, complex care in AF management.5
The above findings are essential for any healthcare system 
as either DM or AF treatment is associated with high healthcare 
costs. Moreover, DM is, and an independent risk factor for AF 
development9,10,32 and their coexistence worsens the outcome 
among patients.33-35 Hence, the awareness of the risk factors, 
early detection of disease and finally, adequate medical care 
is crucial to reduce cardiovascular mortality in such patients.
4.1 | Strengths and limitations
This is the first study in the Middle East population assessing 
the compliance of holistic AF management among patients 
with concomitant DM and the impact on relevant clinical out-
comes. The database is based on a large number of consecu-
tive patients from various medical centres who met precisely 
defined criteria, which enhances the reliability of the analysis 
results. Nevertheless, there are also some limitations, which 
should be considered.
This was an observational study with relatively limited of 
diabetic participants that fulfilled our inclusion criteria for 
the study, therefore some bias and deficiencies of assessment 
may have occurred. The compared groups were not homoge-
neous in terms of concomitant diseases, and some diseases 
(eg. sleep apnoea) may be undiagnosed. In addition, ABC 
noncompliant patients were in majority, in keeping with other 
series.36 As for DM, its diagnosis, duration and specific type 
were unknown, which preclude an appropriate evaluation of 
the impact of DM on the overall cardiovascular risk. In ad-
dition, we did not have information about haemoglobin A1c 
values, which is an indicator of diabetes control in patients 
with DM. Undeniably, such information would enrich the 
content of the study and strengthen the credibility of the re-
sults. Furthermore, because of the retrospective nature of the 
study, we were not able to intervene in the treatment regimen 
that has changed over time, nor do we have data on compli-
ance with drug treatments or therapy cessation, which may 
have implications for outcomes.37,37 Although, our registry 
was conducted in a broad spectrum of clinical settings, in 6 
Gulf region countries – but we would be underpowered to 
perform our analysis by individual country. Due to the ret-
rospective nature of the study, the authors were not able to 
interfere in the treatment regimen that has changed over time. 
Finally, the data from the Gulf SAFE registry was collected 
in 2009-2010, which may affect the reliability of our results 
in relation to current standards. Nevertheless, although the 
ABC pathway was not promoted at that time, the general 
recommendations in accordance with the guidelines for the 
treatment of AF did not differ from those used in prior treat-
ment approaches.
F I G U R E  2  Relationship between events rates and odds ratio of 
clinical outcomes. A, 6-month follow-up. B, 1-year follow-up
Number of criteria 
fulfilled
All-cause mortality Composite outcome
1 y 1 y
OR (95% CI) P value OR (95% CI)
P 
value
AB 0.73 (0.44-1.19) .206 0.78 (0.54-1.12) .180
AC 0.72 (0.38-1.36) .313 1.15 (0.74-1.77) .538
BC 0.53 (0.28-1.01) .053 0.58 (0.37-0.91) .018
Abbreviations: A, anticoagulation; B, symptoms management; C, cardiovascular and other comorbidities 
treatment; CI, confidence interval; OR, odds ratio.
T A B L E  4  Relationship between 
number of ABC criteria fulfilled and 
outcomes: all-cause mortality and composite 
outcome
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5 |  CONCLUSIONS
Integrated AF care, according to the ABC pathway, was in-
dependently associated with a lower risk of all-cause death 
and the composite outcome, in DM patients with AF. This 
highlights the importance of a comprehensive and holistic 
approach to AF management.
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